Laminin 121 E8

Product Inquiry

Laminin 121 E8 Background

Laminin-121 is one of the α1 chain containing laminins. The α1 chain is detected at the 2-cell stage of the pre-implantation mouse embryo and is subsequently expressed mainly in many epithelial tissues during organogenesis. Laminin-121 showed the highest affinity to α6β1 and α7β1 integrins and furthermore, laminin-121 most effectively supported neurite outgrowth.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AtaciceptTACI-IgPhase 3 ClinicalZymogenetics IncGlomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic
Details
PovetaciceptALPN-303; ALPN 30xPhase 3 ClinicalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis
Details
Rozibafusp alfaAMG-570; MEDI-0700Phase 2 ClinicalAmgen IncArthritis, Rheumatoid; Lupus Erythematosus, Systemic
Details
TabalumabLY-2127399Phase 2 ClinicalEli Lilly And CompanyMultiple Sclerosis, Relapsing-Remitting; Dermatomyositis; Arthritis, Rheumatoid; Autoimmune Diseases; Scleroderma, Systemic; Multiple Myeloma; Connective Tissue Diseases; Arthritis, Juvenile; Multiple Sclerosis; Lupus Erythematosus, Systemic; Kidney Failure, Chronic; Pemphigus
Details
UBP-1213UBP-1213Phase 1 ClinicalWuhan Huaxin Kangyuan Biomedicine Co Ltd, Shanghai Junshi Biosciences Co LtdLupus Erythematosus, Systemic
Details
Autologous CAR-T cell therapy expressing the BAFF-ligandLMY-920; LUMT1A22Phase 1 ClinicalLuminary Therapeutics IncSjogren's Syndrome; Scleroderma, Systemic; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell
Details
UBP1213scUBP1213scPhase 1 ClinicalLupus Nephritis; Lupus Erythematosus, Systemic
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
TelitaciceptRCT-18; RC-18; RCT18; RC18ApprovedRemeGen Co LtdMainland ChinaLupus Erythematosus, SystemicRemeGen Co Ltd2021-03-09Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic
Details
BelimumabBmAb; GSK-1550188; HGS-1006ApprovedGlaxosmithkline PlcBenlysta, 倍力腾United StatesLupus Erythematosus, SystemicHuman Genome Sciences Inc2011-03-09Antiphospholipid Syndrome; Leukemia, Lymphocytic, Chronic, B-Cell; Bronchial Diseases; Emphysema; Pulmonary Disease, Chronic Obstructive; Waldenstrom Macroglobulinemia; Hepatitis, Autoimmune; Lymphopenia; Rheumatic Diseases; Sjogren-Larsson Syndrome; Lupus Erythematosus, Systemic; systemic sclerosis-associated interstitial lung disease; Mixed Connective Tissue Disease; Myasthenia Gravis; Glomerulonephritis, Membranous; Lung Diseases, Interstitial; Lupus Nephritis; Graft vs Host Disease; Purpura; Arthritis, Rheumatoid; Scleroderma, Systemic; Myositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Rejection of renal transplantation
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information